Skip to main content
Clinical Trials/CTRI/2012/04/002612
CTRI/2012/04/002612
Recruiting
Phase 4

A Prospective Multi-Centre Registry to Investigate Safety and Effectiveness of Mâ??Sure S (Sirolimus Eluting Coronary Stent). - PRISM

Multimedics0 sites400 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Multimedics
Enrollment
400
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Pms

Investigators

Sponsor
Multimedics

Eligibility Criteria

Inclusion Criteria

  • 1\.The patient must be ï?³ 18 years of age;
  • 2\.Patient is an acceptable candidate for PTCA, Stenting, or Emergent CABG;
  • 3\.Symptomatic ischemic heart disease (CCS class 1 â??4 , Braunwald class IB, IC, IIB, IIC, IIIB,IIIC) and/or objective evidence of myocardial ischemia;
  • 4\.C.T.Oâ??s (Chronic Total Occlusions) and Bifurcation Lesions may also be attempted;
  • 5\.Target lesion stenosis is \>50% and \<100% ;
  • 6\.Target lesions are de novo;
  • 7\.Target lesions \<\=36mm in length (by visual estimation) that can be treated (covered) by one single Registry stent (8 to 40mm in length)
  • 8\.Target lesion located in a major epicardial coronary vessel with reference of \>2\.5 \- \<4\.0mm in diameter (by visual estimation)
  • 9\.Target lesions which can be covered by one stent, no overlapping allowed (lesion stent ratio of at least 1\.5\)

Exclusion Criteria

  • Women of childbearing potential;
  • 2\. Impaired renal function (creatinine \> 2\.0 mg/dl or 180 µmol/l);
  • 3\. Any patient who has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3, a
  • WBC of \<3,000 cells/mm3, or documented or suspected liver disease (including
  • Laboratory evidence of Hepatitis;
  • 4\. Recipient of an organ (Heart, Kidney, Lung or Liver) transplant;
  • 5\. History of CVA or TIA within the last 3 months;
  • 6\. Patient with a concomitant disease having a life expectancy of less than 12 months;
  • 7\. Known allergies or contraindication to mTOR inhibitor class of drugs (Sirolimus),
  • Aspirin, Clopidogrel Bisulphate (Plavixï??), Heparin, Cobalt Chromium/Nickel,

Outcomes

Primary Outcomes

Not specified

Similar Trials